Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
6.75M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
2.89M
-
Shares change
-
+308K
-
Total reported value, excl. options
-
$109M
-
Value change
-
+$11.5M
-
Number of buys
-
23
-
Number of sells
-
-6
-
Price
-
$36.41
Significant Holders of Monopar Therapeutics - Common Stock, $0.001 par value (MNPR) as of Q1 2025
35 filings reported holding MNPR - Monopar Therapeutics - Common Stock, $0.001 par value as of Q1 2025.
Monopar Therapeutics - Common Stock, $0.001 par value (MNPR) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.89M shares
of 6.75M outstanding shares and own 42.76% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.13M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (599K shares), RA CAPITAL MANAGEMENT, L.P. (511K shares), Point72 Asset Management, L.P. (168K shares), ADAR1 Capital Management, LLC (101K shares), Affinity Asset Advisors, LLC (62K shares), MILLENNIUM MANAGEMENT LLC (60.4K shares), VANGUARD GROUP INC (55.2K shares), GEODE CAPITAL MANAGEMENT, LLC (48.5K shares), and MARSHALL WACE, LLP (26K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.